

# Enabling a Phase I Clinical Trial of a Novel Single Domain Mesothelin-Specific Chimeric Antigen Receptor (CAR) T-Cell Therapy for Ovarian Cancer and Other Solid Tumours

Project duration: 2025-3-9 to 2026-3-31

Targeted cancer type:

## Solid tumors (ovarian, pancreatic)

This project will support the manufacturing, safety assessments and clinical trial design for an innovative CAR that targets mesothelin (MesoCAR), in order to enable an eventual Phase I clinical trial for solid-tumors.

Key Investigators:

Project Lead:

**Dr. Brad Nelson**



**Dr. Jennifer Quizi**



Targeted cancer type:

## Solid tumors (ovarian, pancreatic)

Key Investigators:

Project Lead:

**Dr. Brad Nelson**



**Dr. Jennifer Quizi**



2

BioCanRx Funded  
Core Facilities

The Ottawa Hospital's  
Biotherapeutics  
Manufacturing Centre

BC Cancer's Molecular and  
Cellular Immunology Core

Project Value:

**\$1,689,673**

BioCanRx Contribution:  
**\$605,000**

Biotherapeutic:  
**Adoptive cell therapy**

4

Partners



National Research  
Council Canada

Conseil national de  
recherches Canada




## About the project:

While Chimeric Antigen Receptor (CAR) T cell therapies have been successful in treating certain blood cancers, their application to solid tumours remains challenging. To address this, in close collaboration with the National Research Council, the team has developed a novel CAR that uses an innovative “nanobody” against a protein called mesothelin (Meso), which is frequently overexpressed by ovarian, pancreatic and other solid tumours. The team's lead

MesoCAR shows unparalleled efficacy in mouse tumour models, with 100% of mice achieving complete, durable tumour regressions. In collaboration with the Canadian-Led Immunotherapies for Cancer (CLIC) consortium, they are advancing MesoCAR from mouse models to a phase I clinical trial at three Canadian centres. This project will finalize pre-clinical safety assessments of MesoCAR, initiate production of clinical-grade lentivirus and CAR-T cells,

and design a clinical trial protocol. By the end of funding, the team will be ready to manufacture clinical-grade lentivirus and finalize CAR-T cell production methods to enable a Clinical Trial Application to Health Canada in 2026. This project has the ambitious goal of “breaking the solid tumour barrier” using an exceptionally promising made-in-Canada CAR-T cell product.



## Partners:

**BC Cancer Foundation**

**National Research Council of Canada**

**The Ottawa Hospital's Biotherapeutics Manufacturing Centre**

**Ovarian Cancer Canada**

**Total Pledged Partner Contributions: \$1,084,673**

**Total Pledged Matched Contributions: \$846,436**

**Total Leveraged Partner Contributions: \$238,236**

## Key Deliverables

1. Complete the safety assessment of the lead sdMesoCAR construct
2. Initiate clinical-grade manufacturing of sdMesoCAR plasmids and lentivirus
3. Develop release assays and release criteria for sdMesoCAR-T cells
4. Establish a robust clinical trial protocol for a future CTA submission to Health Canada

**The power to kill cancer lies within us. Let's tell our bodies how.**